BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200804
DTEND;VALUE=DATE:20200807
DTSTAMP:20260515T101316
CREATED:20200228T095936Z
LAST-MODIFIED:20200608T092435Z
UID:24358-1596499200-1596758399@www.pharmajournalist.com
SUMMARY:Gene Therapy Immunogenicity
DESCRIPTION:Gene therapies are revolutionizing the therapeutic landscape for rare and inherited diseases. For the field to progress\, however\, there are several unique and complex challenges. Perhaps the most prominent of these challenges is the immune response to gene therapy delivery. \n \nThe inaugural Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better measure\, modulate and predict immune response to your gene therapy candidate. \nUniting industry leaders across the gene therapy space\, this multi-disciplinary forum will enable you to develop more effective and safe gene therapies by discussing how you can: \n\nIdentify and tailor novel capsid proteins for more specific targeting and immunologic evasion\nReduce AAV neutralizing antibodies\nConfidently assess immunosuppression strategies to dampen immune response\n\nAs the only conference dedicated to the immunogenicity of gene therapies\, this will be an unrivalled opportunity to join 80+ like-minded thought-leaders from cross-disciplines to foster new connections and partnerships. \nDownload the full event guide to learn more from companies including BioMarin\, Spark Therapeutics and Novartis.
URL:https://www.pharmajournalist.com/event/gene-therapy-immunogenicity/
LOCATION:MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200812
DTEND;VALUE=DATE:20200813
DTSTAMP:20260515T101316
CREATED:20200624T103810Z
LAST-MODIFIED:20200624T103810Z
UID:26029-1597190400-1597276799@www.pharmajournalist.com
SUMMARY:Vaccines Virtual Conference
DESCRIPTION:Due to the current climate\, we have taken the initiative to launch our very first vaccines conference! Join industry experts from across the globe\, conversing in the latest innovations in COVID-19 and other leading vaccine studies. Brought directly to your home –  listen to leading organisations such as GlaxoSmithKline\, Sanofi\, Pfizer along with leading biotech’s and is completely FREE! Featuring sessions COVID-19 Vaccine Updates\, overcoming manufacturing challenges within the industry \, managing clinical trials during a pandemic\, consideration needed in commercialising your vaccine and more\, this event is crucial to ensure you are up to date with the latest developments in the vaccine space. \n\nURL: https://arena-international.com/vaccine-virtual/
URL:https://www.pharmajournalist.com/event/vaccines-virtual-conference/
LOCATION:Virtual Event
ORGANIZER;CN="Arena International":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200818
DTEND;VALUE=DATE:20200819
DTSTAMP:20260515T101316
CREATED:20200630T114013Z
LAST-MODIFIED:20200630T114013Z
UID:26126-1597708800-1597795199@www.pharmajournalist.com
SUMMARY:Hemophilia Drug Development Summit – Running Digitally for 2020
DESCRIPTION:With the recent Hemlibra approval and the gene therapy revolution\, we are seeing a much-needed race to innovate more effective\, long-lasting and curative therapies for hemophilia and acquired bleeding disorders. \nAs such\, the 3rd Hemophilia Drug Development Summit is going digital and remains dedicated to bringing to patients more effective commercially and clinically translated therapies from small molecules to gene therapies to improve patients’ quality of life. \n \nBringing together over 100 of the world’s leading experts and drug developers\, we discuss how to develop new therapies for a responsive subset of hemophiliac patients\, optimize clinical trial development (setup and management) and discuss the patient/payer paradigm to ensure these novel therapies are affordable and accessible. \nBrought direct to your home office with a jam packed agenda and online virtual networking opportunities\, this exclusive virtual summit will delve into the challenges of treating each patient subset\, as well as hearing the latest advancements in gene therapy and discussing the critical hurdles that need to be overcome to meet the unmet clinical need of all patients. \nJoin us as we unite drug developers and researchers on a dedicated online platform and look to the innovation driving the field towards more long-acting and curative therapies to improve patient quality of life. \nTo know more about Hemophilia Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/hemophilia-drug-development-summit-running-digitally-for-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200827
DTEND;VALUE=DATE:20200828
DTSTAMP:20260515T101316
CREATED:20200716T135808Z
LAST-MODIFIED:20200716T135808Z
UID:26353-1598486400-1598572799@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200831
DTEND;VALUE=DATE:20200903
DTSTAMP:20260515T101316
CREATED:20200703T082824Z
LAST-MODIFIED:20200703T082824Z
UID:26146-1598832000-1599091199@www.pharmajournalist.com
SUMMARY:Blood-Brain Barrier (BBB) Summit
DESCRIPTION:Going digital in its 2nd year\, the Blood-Brain Barrier (BBB) Summit is the industry’s definitive BBB conference focused on sharing the latest scientific advances\, data and key lessons learned for transporting more drugs across the BBB. \nWith a heavy focus on biologics\, for neurodegenerative diseases\, this summit will discuss topics such as quantitative methodologies for measuring amount and distribution of antibodies in the brain\, using PKPD systems to improve translation and predict clinical outcomes and importantly\, progress in the validation of approaches and technologies which enhance BBB transition. \nMoreover\, this meeting also aims to deepen your understanding of intracellular trafficking and receptor binding\, pharmacokinetics and protein engineering to drive the clinical applicability of receptor mediated transcytosis. The 2nd BBB Summit delves into identifying gaps in the physiology of the BBB and questions the extent of the relationship between the BBB and different disease states in various neurodegenerative diseases as well as uncovering what makes neural exosomes efficient BBB drug delivery tools. \nJoin fellow BBB specialists virtually to scrutinize progress of existing approaches to deliver more of your biologic therapeutic across the BBB to develop a clinically defining neurodegenerative treatment. \nTake a look at the full event guide here.
URL:https://www.pharmajournalist.com/event/blood-brain-barrier-bbb-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR